Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
LNA043- ANGPTL3 agonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT03275064 (CLNA043X2202)
Knee osteoarthritis
Phase 2
133
Articular cartilage bi-layer collagen organisation evaluated with MRI and measured
in milliseconds (ms) (Part A only)
Number of patients with any adverse events, serious adverse events and death
(Part A and Part B)
Change in cartilage volume/thickness in the index region (Part B only)
NCT04864392 ONWARDS (CLNA043A12202)
Knee osteoarthritis
Phase 2
550
Change from baseline in the cartilage thickness of the medial compartment of the
knee as assessed by imaging
Arms Intervention
LNA043 40 mg Part B
LNA043 20 mg Part B
LNA043 20 mg Part A
Placebo Part A
Placebo Part B
LNA043 injection to the knee with dosing regimen A
LNA043 injection to the knee with dosing regimen B
LNA043 injection to the knee with dosing regimen C
LNA043 injection to the knee with dosing regimen D
Placebo injection to the knee
Target Patients
Patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B)
Read-out Milestone(s)
2022
Patients with Symptomatic knee osteoarthritis
Primary 2024
Publication
TBD
TBD
56 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation